Business Wire

ThreatNG Security Offers Free Access to Their Groundbreaking Security Platform for Organizations to Assess Cloud and SaaS Vulnerabilities

28.2.2023 17:00:00 EET | Business Wire | Press release

Share

ThreatNG, a cybersecurity company dedicated to empowering organizations of all sizes to manage their external attack surface and digital risks, has announced the release of its agentless Cloud and SaaS Exposure Assessment Module. The company also announced free access to organizations to this groundbreaking platform to assess their external risk for a limited time.

The ThreatNG “Cloud and SaaS Exposure” Module supports the following vendors and technology categories:

- Amazon Web Services (AWS)
- Microsoft Azure
- Google Cloud Platform (GCP)
- Analytics
- Business Intelligence (BI)
- Customer Relationship Management (CRM)
- File Sharing
- Human Resources
- Security
- Video Telephony

ThreatNG continues to redefine External Attack Surface Management (EASM), Digital Risk Protection, and Security Ratings by announcing the availability of its Agentless Cloud and SaaS Exposure Assessment Module. Requiring only a domain and organization name, ThreatNG users can perform Outside-In Discovery, Assessment, Reporting, and Monitoring of their Cloud and SaaS Footprint, uncover Exposed Open Cloud Buckets, bring to light Unsanctioned Implementations (Shadow IT), and call to attention Brand Impersonations (Cybersquats) without using agents, credentials, API connections, browser plugins, and any other means that require prior knowledge.

ThreatNG further empowers its users by providing a differentiated, unmatched, and holistic approach by extending discovery and assessment of all Internet-exposed online applications, repositories, APIs, platform-as-a-service (PaaS), infrastructure-as-a-service (IaaS), and vendor technologies interconnected with Cloud and SaaS implementations.

“As more critical data and functions are migrating to the cloud, it becomes much more important for organizations to have visibility of all their digital assets exposed to the public and address all potential risks and threats. Our Cloud and SaaS Exposure module empower users with a proactive outside-in perspective,” said Eric Gonzales, founder of ThreatNG. “We are so confident in our technology’s capability that we are willing to provide organizations of all sizes with a free discovery and risk assessment of their Cloud and SaaS environments.”

To learn more about ThreatNG and its Cloud and SaaS Exposure Assessment capabilities, visit the company’s website, www.threatngsecurity.com/cloudexposure.

Cloud and SaaS Environments are continuously evolving. With new instances appearing, this constant change makes it challenging to keep an accurate inventory of sanctioned implementations and maintain good cyber hygiene overall. This growing Cloud and SaaS sprawl feeds into the ever-increasing problem of Shadow IT (Unsanctioned Implementations) and Cybersquats (Brand Impersonations). This uncontrollable sprawl has also led to increased security risks and exposures, a growth in phishing attacks abusing SaaS platforms, and cloud assets compromised more than on-premise assets (Verizon 2022 Data Breach Investigations Report).

Cloud and SaaS Impersonations (Cybersquats) and Exposed Data within Open Cloud Buckets are growing problems with organizations of all sizes and their Third Parties. Still, they are out of scope within most External Attack Surface Management (EASM), Digital Risk Protection, and Security Rating Services. ThreatNG unites these solution capabilities and empowers users to seamlessly bring Cloud and SaaS into the fold of Asset Inventory, Security & Governance, Subsidiary Security Monitoring, Third-Party Security Assessments, and Brand Protection through their innovative external discovery and assessment requiring only a domain and organization name.

Support for all of the above is available today and accompanied by all of the following investigation modules provided to all ThreatNG users:

  • Domain Intelligence
  • Technology Stack
  • Sensitive Code Exposure
  • Online Sharing Exposure
  • Search Engine Exploitation
  • Sentiment and Financials
  • Archived Web Pages
  • Social Media
  • Dark Web

Contact ThreatNG Security today for a Free 30-Day Evaluation of their Cloud and SaaS Exposure Assessment Module.

About ThreatNG

ThreatNG is redefining external attack surface management (EASM), digital risk protection, and security ratings with a platform of unmatched breadth, depth, and capabilities in managing technical and business threats across the dark, deep, and open web. Living up to the company mantra (“Security Centric; Not Exclusive”), ThreatNG provides a configurable solution to target, discover, and assess digital assets across a definable ecosystem of organizations, subsidiaries, partners, third parties, supply chains, and customers. Bolstered and maintained by the open source intelligence (OSINT) experts at DarcSight Labs, ThreatNG empowers organizations of all types and sizes to uncover, understand, and manage their external digital threats.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Price
Email: erin@threatngsecurity.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye